Khan Abdul Basit, Khan Rizwan Hasan
Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.
Protein Pept Lett. 2023;30(11):900-912. doi: 10.2174/0109298665247757231020044633.
Alzheimer's disease, a neurodegenerative disease, is a progressive and irreversible disease that has become a global challenge due to its increasing prevalence and absence of available potential therapies. Protein misfolding and aggregation are known to be the root of several protein neurodegenerative diseases, including Alzheimer's disease. Protein aggregation is a phenomenon where misfolded proteins accumulate and clump together intra-or extracellularly. This accumulation of misfolded amyloid proteins leads to the formation of plaquesin the neuronal cells, also known as amyloid β plaques. The synthesis of amyloid β plaques and tau protein aggregation are the hallmarks of Alzheimer's disease. Potential therapeutics must be developed in conjunction with an understanding of the possible root cause involving complex mechanisms. The development of therapeutics that can inhibit protein misfolding and aggregation, involved in the pathogenesis of Alzheimer's disease, could be one of the potential solutions to the disease.
阿尔茨海默病是一种神经退行性疾病,是一种进行性且不可逆的疾病,由于其患病率不断上升且缺乏有效的潜在治疗方法,已成为一项全球性挑战。已知蛋白质错误折叠和聚集是包括阿尔茨海默病在内的几种蛋白质神经退行性疾病的根源。蛋白质聚集是一种错误折叠的蛋白质在细胞内或细胞外积累并聚集在一起的现象。这种错误折叠的淀粉样蛋白的积累导致神经元细胞中形成斑块,也称为淀粉样β斑块。淀粉样β斑块的合成和tau蛋白聚集是阿尔茨海默病的标志。必须结合对涉及复杂机制的可能根本原因的理解来开发潜在的治疗方法。开发能够抑制参与阿尔茨海默病发病机制的蛋白质错误折叠和聚集的治疗方法,可能是解决该疾病的潜在方案之一。